We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Juno Therapeutics

News List

Juno Therapeutics Spinout Raises $90M biospace
March 09, 2018
JW Therapeutics, headquartered in Shanghai, China, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec in 2016, closed a Series A financing worth $90 million.
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Im biospace
March 07, 2018
Celgene today announced that it has completed the acquisition of Juno Therapeutics, Inc. As a result, the common stock of Juno will no longer be listed for trading on the NASDAQ Global Select Market
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 fiercebiotech
January 23, 2018
Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category.
Juno Therapeutics signs three license agreements biospectrumasia
December 12, 2017
Through its agreement with Eli Lilly and Company, Juno will acquire a license to the GSI known as LY3039478 which is a product candidate that has been studied in 411 patients and healthy volunteers